• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Clinical value of a new method of therapeutic control of heparin].

作者信息

Pizzuto J, Garcia S, de la Paz Reyna M, Morales M R, Avilés A, Zavala B, Ponce L, Gaos C

出版信息

Arch Inst Cardiol Mex. 1978 Mar-Apr;48(2):373-86.

PMID:666447
Abstract

A modification of thrombosis time (TT) for therapeutic control of heparin (TTDT), is described. A useful dose of heparin increases plasma TT, which on dilution with fresh plasma rich in platelets (250 +/- 50 x 10(9)/1) at a dilution of 1:4 to 1:8 (+/-20%), causes the increased plasma TT to return to normal values. Three coagulation tests used simultaneously were tried: plasma recalcification time, partially activated thromboplastin time, and TT, used simultaneously in 30 samples of platelet rich fresh normal plasma with different concentrations of heparin (0.05 to 1.0 mu/ml). Results show that modified TT is the most sensitive and reproducible test to detect varying heparin dosage. Fifty two patients without coagulation deficiencies and with various clinical thrombi, and 22 with generalized intravascular coagulation (CID) treatment with 100mu of heparin XK of body weight every 4 to 6 hours, were studied. Results are described. Advantages of TRDT for therapeutic control of heparin are discussed.

摘要

相似文献

1
[Clinical value of a new method of therapeutic control of heparin].
Arch Inst Cardiol Mex. 1978 Mar-Apr;48(2):373-86.
2
Clotting, activated partial thromboplastin and coagulation times in monitoring heparin therapy.在监测肝素治疗时的凝血、活化部分凝血活酶时间和凝血时间。
Ann Clin Lab Sci. 1979 Nov-Dec;9(6):494-500.
3
Clinical evaluation of new global clotting assay for monitoring of LMWH treatment: pilot study.用于监测低分子肝素治疗的新型全球凝血检测的临床评估:初步研究。
Int Angiol. 1998 Jun;17(2):69-79.
4
[Monitoring of heparin therapy with activated recalcification time].[用活化复钙时间监测肝素治疗]
Z Gesamte Inn Med. 1981 Feb 15;36(4):102-6.
5
[Laboratory controls of heparin therapy with thrombin time, partial thromboplastin time and activated recalcification time].[肝素治疗的实验室控制:凝血酶时间、部分凝血活酶时间和活化复钙时间]
Z Gesamte Inn Med. 1989 Apr 15;44(8):235-40.
6
[The kaolin-activated recalcification test in the screening of coagulation disorders and in the control of anticoagulant therapy].
Quad Sclavo Diagn. 1977 Jun;13(2):167-75.
7
Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology.弥散性血管内凝血诊断与管理指南。英国血液学标准委员会。
Br J Haematol. 2009 Apr;145(1):24-33. doi: 10.1111/j.1365-2141.2009.07600.x. Epub 2009 Feb 12.
8
On the value of the activated partial thrombo-plastin time (aptt) in monitoring heparin therapy.活化部分凝血活酶时间(APTT)在监测肝素治疗中的价值
Thromb Haemost. 1976 Jun 30;35(3):592-7.
9
The monitoring of heparin administration by screening tests in experimental dogs.通过筛选试验对实验犬肝素给药进行监测。
Res Vet Sci. 2001 Apr;70(2):101-8. doi: 10.1053/rvsc.2000.0447.
10
[Measurement of activated whole blood coagulation as a control parameter for heparin dosage in hemodialysis].[测定活化全血凝固作为血液透析中肝素剂量的控制参数]
Z Urol Nephrol. 1984 Aug;77(8):465-71.